Your Heart-Rate Variability Moves With Your Cycle. Your Wearable Should Know That.

Your Heart-Rate Variability Moves With Your Cycle. Your Wearable Should Know That.

Key takeaways

  • In most studies of naturally cycling women, HRV is higher in the first half of the cycle and lower in the second half. The reported difference is modest, roughly 3-9% in time-domain measures.
  • Combined hormonal contraceptives appear to lower HRV, and midlife women show lower RMSSD than younger women. A wearable score without this context can be misread.
  • The evidence is observational and uses mixed devices and methods. HRV is a signal that varies with hormones, not a hormone test and not a diagnosis.

Why HRV and Hormones?

Heart-rate variability (HRV) is the small beat-to-beat variation in your heart rhythm. It reflects how the autonomic nervous system balances rest and arousal. Sleep, alcohol, training load, illness and stress all move it. Reproductive hormones also act on the autonomic nervous system, so it is plausible that estrogen and progesterone shift HRV across the month. Wearables now report HRV every night, which makes the question practical: if your score drops in the second half of your cycle, is something wrong?

What the New Review Found

In January 2026, de Jager and colleagues published a living systematic review in Sports Medicine covering wearable-derived HRV in females. They searched five databases up to December 2025, screened 239 unique records and included 16 studies with 19,322 participants in total.

For naturally menstruating women (15 studies), most reported higher HRV early in the cycle and lower HRV late in the cycle. Eight of ten studies that reported RMSSD, a common vagally mediated measure, found lower values in the second half. The size of the change was small: the abstract reports 3-9% for time-domain measures. Frequency-domain results (LF, HF, LF/HF) were inconsistent.

For hormonal contraceptives (6 studies), combined pill users tended to show lower HRV than naturally cycling women, while progestin-only users looked closer to the natural pattern. For life stages (3 studies), women aged 42-56 had lower RMSSD than younger women, and results by menopausal stage varied. The review found no pregnancy-specific data.

How Sure Are We?

Not very. The studies used different devices (PPG and ECG), recording lengths (from seconds to overnight), HRV metrics and phase definitions, so the authors could not pool results in a meta-analysis. Only seven studies confirmed cycle phase biochemically; the rest relied on self-report or calendar estimates. Sleep, alcohol, training and stress were rarely controlled. The review's "moderate" description refers to a median Newcastle-Ottawa quality score of 7 out of 9, not to a formal certainty-of-evidence grade.

Key figures

For Clinicians

  • Design: Living systematic review (PRISMA, PRISMA-LSR), OSF-registered; search from inception to 17 Dec 2025; 16 observational studies, n = 19,322 (range 7 to 11,590); median NOS 7/9.
  • Menstrual cycle: 15 studies (n = 15,273). Lower RMSSD in the late cycle in 8 of 10 reporting studies; SDNN similar in about two-thirds. Time-domain difference reported as 3-9% in the abstract; frequency-domain findings heterogeneous.
  • Contraception: 6 studies (n = 16,325). Combined hormonal contraceptive use associated with lower HRV; one included study reported a lower RMSSD amplitude in pill users (-0.51 vs +4.65 ms, p < 0.001). Two studies mixed users and non-users.
  • Life stages: 3 studies (n = 1,906). Lower RMSSD at 42-56 years vs younger; menopause classification inconsistent (age alone in two studies).
  • Limitations: No meta-analysis possible; device and metric heterogeneity; mostly non-biochemical phase confirmation; uncontrolled confounders; English-only; no GRADE rating.
  • Practical point: Interpret wearable HRV against the patient's own cycle-phase and medication context, not population norms. Do not use a wearable HRV value to infer hormone concentrations or ovulation status.

What's New in Regulation

United States. On 6 January 2026 the FDA issued a revised General Wellness policy for low-risk devices, replacing the 2019 version. Law-firm summaries state that non-invasive, sensor-based wearables reporting physiologic parameters such as HRV can stay outside device regulation if the intended use is strictly wellness. A product loses that status if it claims clinical accuracy or "medical grade" performance, references diseases or diagnostic thresholds, or guides clinical action.

European Union. On 16 December 2025 the European Commission proposed targeted amendments to the MDR and IVDR (COM(2025) 1023 final) to simplify certification and reduce administrative burden. At the time of writing, it was still in the legislative process.

What This Means for Patients

If you track HRV, note where you are in your cycle and whether you use hormonal contraception. A lower reading in the second half of a cycle can be an expected pattern, not a sign of poor recovery. Compare against your own baseline over several cycles and watch trends, not single nights. If you notice persistent changes, irregular cycles, or symptoms such as hot flashes, bring your data and your questions to your doctor. A wearable can add context to that conversation; it cannot replace a hormone test.

6Letters is building non-invasive hormone-tracking tools, including MOJO KING and MOJO QUEEN (launching soon). We think context like cycle phase matters. Learn more at https://6letters.co.kr.

Disclaimer: This article is educational and not medical advice. Consult a physician about your health.

References

  1. de Jager E, Caulfield B, Angelidi E, MacNamee B, Holden S. Wearable-Derived Heart Rate Variability Across the Menstrual Cycle, Hormonal Contraceptive Use, and Reproductive Life Stages in Females: A Living Systematic Review. Sports Medicine. 2026;56(5):1153-1173. Published 17 Jan 2026. DOI: 10.1007/s40279-025-02388-y. PMID: 41545627. https://pmc.ncbi.nlm.nih.gov/articles/PMC13198475/
  2. U.S. FDA. General Wellness: Policy for Low Risk Devices (revised guidance, issued 6 Jan 2026). https://www.fda.gov/media/90652/download
  3. Covington & Burling LLP. FDA Issues Revised Guidance on General Wellness Products. 8 Jan 2026. https://www.cov.com/en/news-and-insights/insights/2026/01/fda-issues-revised-guidance-on-general-wellness-products
  4. Obelis. EU Proposal to simplify MDR and IVDR: what it is and why it matters (describes Commission proposal COM(2025) 1023 final, 16 Dec 2025). https://www.obelis.net/news/eu-proposal-to-simplify-mdr-and-ivdr-what-it-is-and-why-it-matters/